Opinion|Videos|April 23, 2025
Overcoming Barriers and Improving CAR T Care in Academic and Community Settings
Author(s)Caron A. Jacobson, MD, MMSc, Peter Riedell, MD
Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When considering early referral of CAR T, what challenges and/or barriers remain?
- How do you manage post–CAR T follow-up care between academic and community settings?
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
Revisit Every OncLive On Air Episode From June 2026
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
5